U.S. Physical Therapy, Inc. Stock

Equities

USPH

US90337L1089

Healthcare Facilities & Services

Market Closed - Nyse 04:00:02 2024-04-15 pm EDT 5-day change 1st Jan Change
101 USD -1.65% Intraday chart for U.S. Physical Therapy, Inc. -5.64% +8.45%
Sales 2024 * 637M Sales 2025 * 669M Capitalization 1.55B
Net income 2024 * 43M Net income 2025 * 47M EV / Sales 2024 * 2.38 x
Net cash position 2024 * 32.94M Net cash position 2025 * 59.26M EV / Sales 2025 * 2.22 x
P/E ratio 2024 *
36.2 x
P/E ratio 2025 *
33.2 x
Employees 5,310
Yield 2024 *
1.71%
Yield 2025 *
1.75%
Free-Float 85.58%
More Fundamentals * Assessed data
Dynamic Chart
U.S. Physical Therapy, Inc. acquired 50% stake in Nine-Clinic Physical Therapy And Hand Therapy Practice for $16.4 million. CI
JPMorgan Adjusts U.S. Physical Therapy's Price Target to $117 From $99, Reiterates Overweight Rating MT
US Physical Therapy Reports Change in 2024 Medicare Rate Reduction MT
U S Physical Therapy Inc /nv Insider Sold Shares Worth $274,441, According to a Recent SEC Filing MT
Barrington Ups Price Target on U.S. Physical Therapy to $122 From $120 After Strong Q4 Beat, Keeps Outperform Rating MT
Transcript : U.S. Physical Therapy, Inc., Q4 2023 Earnings Call, Feb 29, 2024
US Physical Therapy Reports Higher Q4 Results; Ups Quarterly Dividend MT
U.S. Physical Therapy, Inc. Increases Quarterly Dividend, Payable on April 5, 2024 CI
Earnings Flash (USPH) U.S. PHYSICAL THERAPY Posts Q4 Revenue $134.6M, vs. Street Est of $150.3M MT
U.S. Physical Therapy, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Barrington Adjusts Price Target on U.S. Physical Therapy to $120 From $111, Maintains Outperform Rating MT
JPMorgan Adjusts Price Target on U.S. Physical Therapy to $99 From $108, Maintains Overweight Rating MT
U S Physical Therapy Inc /nv Insider Sold Shares Worth $131,085, According to a Recent SEC Filing MT
Barrington Cuts Price Target on U.S. Physical Therapy to $111 From $124 on 'Tough Stock Market Environment', Reiterates Outperform Rating MT
Tranche Update on U.S. Physical Therapy, Inc.'s Equity Buyback Plan announced on March 18, 2009. CI
More news
1 day-1.63%
1 week-3.50%
Current month-9.01%
1 month-3.61%
3 months+8.51%
6 months+17.96%
Current year+10.26%
More quotes
1 week
101.76
Extreme 101.76
108.85
1 month
101.76
Extreme 101.76
113.63
Current year
91.69
Extreme 91.69
113.63
1 year
78.08
Extreme 78.08
124.11
3 years
73.30
Extreme 73.3
131.50
5 years
45.13
Extreme 45.13
148.48
10 years
29.56
Extreme 29.56
148.48
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 03-10-31
Director of Finance/CFO 61 20-11-08
Chief Operating Officer 59 21-06-30
Members of the board TitleAgeSince
Chief Executive Officer 60 03-10-31
Director/Board Member 72 05-02-22
Director/Board Member 70 07-09-05
More insiders
Date Price Change Volume
24-04-15 101 -1.65% 82,954
24-04-12 102.7 -1.63% 98,999
24-04-11 104.4 +0.24% 81,645
24-04-10 104.2 -2.48% 104,694
24-04-09 106.8 -0.23% 35,045

Delayed Quote Nyse, April 12, 2024 at 04:00 pm EDT

More quotes
U.S. Physical Therapy, Inc. is engaged in physical therapy operations and provides industrial injury prevention services. The Company is engaged in physical therapy operations primarily through its subsidiary, clinic partnerships. The Company's physical therapy operations consist of physical therapy and occupational therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventive care, rehabilitation of injured workers and neurological injuries. It operates approximately 678 outpatient physical therapy clinics in 42 states. The Company's industrial injury prevention services include onsite injury prevention and rehabilitation, performance optimization, post offer employment testing, functional capacity evaluations, and ergonomic assessments. It performs these services through Industrial Sports Medicine Professionals, consisting primarily of specialized certified athletic trainers (ATCs).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
102.7 USD
Average target price
119.3 USD
Spread / Average Target
+16.16%
Consensus